Torsades de Pointes Associated With High Dose Levomethadyl Acetate (ORLAAM)

• NCJ Number: 192499
• Journal: Journal of Addictive Diseases Volume: 20 Issue: 4 Dated: 2001 Pages: 7-14
• Author(s): Robert L. Deamer; Douglas R. Wilson; Daniel S. Clark; John G. Prichard
• Date Published: 2001
• Length: 8 pages
• Publication Format: Article
• Publication Type: Report (Technical)
• Language: English
• Country: United States of America

Annotation

This article studies the claim that predisposed patients on high doses of LAAM may be at risk for developing TdP.

Abstract

A patient undergoing management of heroin dependency with high dosages of the long-acting methadone derivative levomethadyl acetate HCl (LAAM; ORLAM) developed a prolonged QTc interval and polymorphic QRS complexes on EKG consistent with torsades de pointes (TdP). The patient was taking other drugs known to prolong the QTc interval (fluoxetine and IV cocaine), and those known to antagonize the activity of the P450 enzymes responsible for the metabolism of LAAM and its active metabolite (fluoxetine, cocaine, and marijuana). No previous reports have appeared in the literature attributing this adverse event to LAAM therapy; however, five similar cases have been reported to the manufacturer. Animal studies indicate that LAAM and metabolites prolong the action potential duration of myocardial cells. Predisposed patients on high doses of LAAM may be at risk for developing TdP. Patients being treated with LAAM should receive dosages consistent with guidelines and be evaluated for concomitant diseases, interacting drug therapies, and EKG abnormalities. Figures, tables, references